News
OncClub
All Oncology News
Pipeline Report
Media
Insights
Medical World News
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
The Talk
Conferences
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
PER Events
Scientific Interchanges
State of the Science Summit / IPC
Webinars
Partners
Publications
OncologyLive
Oncology Fellows
Supplements And Featured Publications
All Publications
CME/CE
Resources
Interactive Tools
Learning Modules
Presentations
Sponsored
Subscribe
Print Subscription
eNewsletter

logo
Spotlight
OncClub: Join the Chat on Trending Trials in Cancer
2023 nominations are open for Giants of Cancer Care®
In-person and virtual events just for HCPs
Register | New Options for Advanced HCC
Specialty
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
OncClub
All Oncology News
Pipeline Report
Insights
Medical World News
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
The Talk
Conference Coverage
Conference Listing
Giants of Cancer Care
PER Events
Scientific Interchanges
State of the Science Summit / IPC
Webinars
Partners
OncologyLive
Oncology Fellows
Supplements And Featured Publications
All Publications
CME/CE
Interactive Tools
Learning Modules
Presentations
Sponsored
Print Subscription
eNewsletter
Advertisement
Breast Cancer
| Lung Cancer
| Gastrointestinal Cancer
| Genitourinary Cancers
| Ovarian Cancer
| Prostate Cancer
| Melanoma & Skin Cancer
| Mantle Cell Lymphoma
| Myeloproliferative Neoplasms
| Biosimilars
| Brain Cancer
| Business Management
| CAR T-cell Therapy
| COVID-19
| Chronic Lymphocytic Leukemia
| Colorectal Cancer
| Disparities in Cancer Care
| Global Oncology
| Gynecologic Oncology
| Head & Neck Cancers
| Hematologic Oncology
| Immuno-Oncology
| Multiple Myeloma
| Neoadjuvant HER2+
| Non-Hodgkin Lymphoma
| Oncology Nursing News
| Pediatric Oncology
| Precision Medicine in Oncology®
| Sarcomas/TGCT
| Supportive Care
| Urothelial Cancer
View All >>
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
  • Business Management
  • CAR T-cell Therapy
  • COVID-19
  • Chronic Lymphocytic Leukemia
  • Colorectal Cancer
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Global Oncology
  • Gynecologic Oncology
  • Head & Neck Cancers
  • Hematologic Oncology
  • Immuno-Oncology
  • Lung Cancer
  • Mantle Cell Lymphoma
  • Melanoma & Skin Cancer
  • Multiple Myeloma
  • Myeloproliferative Neoplasms
  • Neoadjuvant HER2+
  • Non-Hodgkin Lymphoma
  • Oncology Nursing News
  • Ovarian Cancer
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Prostate Cancer
  • Sarcomas/TGCT
  • Supportive Care
  • Urothelial Cancer

SPOTLIGHT -

OncClub: Join the Chat on Trending Trials in Cancer
| 2023 nominations are open for Giants of Cancer Care®
| In-person and virtual events just for HCPs
| Register | New Options for Advanced HCC

Jesus G. Berdeja, MD

home / authors / jesus-g-berdeja-md

Articles


Dr Berdeja on the Safety and Efficacy of BMS-986393 in R/R Multiple Myeloma

December 11th 2022

Jesus G. Berdeja, MD, discusses the investigation of BMS-986393 in patients with relapsed/refractory multiple myeloma.

Read More


Dr. Berdeja on Dosing JNJ-4528 in Relapsed/Refractory Multiple Myeloma

July 8th 2020

Jesus G. Berdeja, MD, discusses the dosing of the investigational CAR T-cell product JNJ-4528 in patients with ​relapsed/refractory multiple myeloma.

Read More


Dr. Berdeja on Next Steps With JNJ-4528 in Relapsed/Refractory Myeloma

June 25th 2020

Jesus G. Berdeja, MD, discusses next steps for the phase 2 CARTITUDE-1 study with JNJ-4528 in relapsed/refractory myeloma.

Read More


Dr. Berdeja on Updated CARTITUDE-1 Results With JNJ-4258 in Multiple Myeloma

June 15th 2020

Jesus G. Berdeja, MD, discusses updated safety results from the ongoing phase 1b/2 CARTITUDE-1 trial (NCT03548207) with the CAR T-cell therapy JNJ-4528 in multiple myeloma.

Read More


Dr. Berdeja on FDA Approval of Frontline Daratumumab Plus VMP in Multiple Myeloma

May 8th 2018

Jesus G. Berdeja, MD, director of Myeloma Research, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of frontline daratumumab (Darzalex) in combination with bortezomib (Velcade), melphalan, and prednisone (VMP) for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).

Read More

Latest Conference Coverage

Currently Available Treatment Options for Patients With R/R DLBCL

Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

Both Gastric and Breast HER2 Scoring Algorithms Applicable in mCRC Testing

Encorafenib Plus Cetuximab and Chemotherapy Demonstrates Safety, Efficacy in BRAF V600E–Mutant mCRC

View More Latest Conference Coverage
Recent Content
View More Recent Content
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact